Also, quarterly rebalancing for GRNY:
| |
| |
|
OT: Stock and Investment Thread
- Thread starter RU05
- Start date
I love Tom Lee because he is thorough. But him saying the PPI report wasn’t problematic because the worst is yet to come inflation-wise isn’t comforting.
And why doesn’t he realize that MSTR is a Ponzi? Or maybe he knows but he also knows that it’s still an early stage Ponzi and therefore it’s still a good Ponzi.
SS is a ponzi and that's been going on for 90 years now.
I love Tom Lee because he is thorough. But him saying the PPI report wasn’t problematic because the worst is yet to come inflation-wise isn’t comforting.
And why doesn’t he realize that MSTR is a Ponzi?
Admittedly I don’t follow crypto stuff closely but I did catch an analyst discussing Saylor’s strategy and he mentioned the paying of preferred dividends to shareholders despite Bitcoin holdings not paying interest. Meanwhile, the company’s revenues are basically stagnating or growing very slowly at best.SS is a ponzi and that's been going on for 90 years now.
Saylor is quite the salesman.
They will be one of the richest companies in the world or the cause of a black swan event. No in between
I prefer my ponzis to be voluntarySS is a ponzi and that's been going on for 90 years now.
I think its too short term of a double to carry any real significance.
But the stock does need to cool off.
Imagine all the homeless older folks without SS. I suppose they could be incarcerated for three hots and a cot which would be a boon for the private prison industry.
Because the company he is the chairman of BMNR will also b a ponzi so might as well ride together
Tonix stock halted on pending news. We shall see very soon!Yes it is on Friday 8/15. It could come early tomorrow, hope it isn’t delayed like Kalvista & Novovax’s recent (eventual) proposals.
UPDATE (but stock still halted):
Approved!
Tonix Pharmaceuticals Holding Corp. (TNXP.NaE) , a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. Tonmya is a first-in-class, non-opioid, once-daily bedtime analgesic with a unique sublingual (under the tongue) formulation that is designed for rapid absorption into the bloodstream. Tonmya is the first new FDA-approved therapy for the treatment of fibromyalgia in over 15 years.
Last edited:
This is going to skyrocket once the hold is lifted.Tonix stock halted on pending news. We shall see very soon!
UPDATE (but stock still halted):
Approved!
Tonix Pharmaceuticals Holding Corp. (TNXP.NaE) , a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. Tonmya is a first-in-class, non-opioid, once-daily bedtime analgesic with a unique sublingual (under the tongue) formulation that is designed for rapid absorption into the bloodstream. Tonmya is the first new FDA-approved therapy for the treatment of fibromyalgia in over 15 years.
hope you bought shares when it sold off this morning! I own quite a few
I did buy shares! Not a crazy amount since you never know with the FDA, but enough for a full position in my personal account. I was thinking about call options, but went with shares since it may be good to hold for a while.This is going to skyrocket once the hold is lifted.
hope you bought shares when it sold off this morning! I own quite a few
First treatment in 15 years, non-opioid, phase 3 data looks strong. Might be a home run medication.
Pharma should find a way to research medications inside of rehabs.
cyclobenzaprine has always been the pain reliever and muscle relaxer of choice there. Kids have been chewing it, snorting it, etc for years. They probably could have discovered this a long time ago
I see TNXP up 15% in extended, fairly muted move given it was down 13% during normal trading hours, and this sounds like the type of news that makes these bio's jump 100% or more.
If it's not crazy monday morning I'll look to pick some up.
If it's not crazy monday morning I'll look to pick some up.
I have some JOBY stock. The platform is an eVTOL. These tests like the one posted are steps necessary for certification from the FAA. So while people may not think this flight is a big deal because of the distance, it is a requirement for the certification process for the airframe.
And yes, it is like a helicopter, but it can also fly like a fixed wing. The main driver in the concept is that this is an electric VTOL.
Nice run for TEM over the past week or two. A lot of these AI application companies are going to be big winners.
TA for BABA looks good:
Alibaba – Recent pattern improvement could help lift BABA
Support- $116, $112, Resistance- $158, $188
Source: Fundstrat, TradingView
Alibaba is being added again to the UPTICKS list following recent stabilization ahead of earnings
Technically I view the recent strength in BABA +0.07% in recent weeks as being a constructive development which makes this attractive following its big setback into early June.
The minor consolidation in BABA +0.07% morphed into a triangle pattern that has just been resolved by structural improvement, representing an upside breakout to this recent pattern.
Volume gave an early hint to a possible breakout following the highest volume session on July 15th since mid-April (34 million shares), coinciding with a sharp upward gap. Its subsequent consolidation in mid-to-late July has now been resolved higher once again following today’s rally to the highest levels since mid-May.
This is quite technically bullish for BABA +0.07% and should help to drive this back to challenge and eventually exceed the prior peak from mid-March at $148.43.
Overall, this positive technical price action in recent days directly coincided with the bullish economic news announced on China’s M1 Money growth levels from last week.
Bottom line, given a good technical likelihood of a further decline in the US Dollar in the weeks to come, I like adding BABA +0.07% back to UPTICKS at its Wednesday 8/13/25 close of $126.86.
Alibaba – Recent pattern improvement could help lift BABA
Support- $116, $112, Resistance- $158, $188
Source: Fundstrat, TradingView
Alibaba is being added again to the UPTICKS list following recent stabilization ahead of earnings
Technically I view the recent strength in BABA +0.07% in recent weeks as being a constructive development which makes this attractive following its big setback into early June.
The minor consolidation in BABA +0.07% morphed into a triangle pattern that has just been resolved by structural improvement, representing an upside breakout to this recent pattern.
Volume gave an early hint to a possible breakout following the highest volume session on July 15th since mid-April (34 million shares), coinciding with a sharp upward gap. Its subsequent consolidation in mid-to-late July has now been resolved higher once again following today’s rally to the highest levels since mid-May.
This is quite technically bullish for BABA +0.07% and should help to drive this back to challenge and eventually exceed the prior peak from mid-March at $148.43.
Overall, this positive technical price action in recent days directly coincided with the bullish economic news announced on China’s M1 Money growth levels from last week.
Bottom line, given a good technical likelihood of a further decline in the US Dollar in the weeks to come, I like adding BABA +0.07% back to UPTICKS at its Wednesday 8/13/25 close of $126.86.
Can someone explain how Robinhood’s prediction markets for pro and college football is any different than DraftKings betting?
Also, what’s the functional difference between a stablecoin and a universal digital gift card (use anywhere w/ no fees)? I heard stablecoins were recently dropped to attendees at a conference in Bermuda for use at local gift shops.
Also, what’s the functional difference between a stablecoin and a universal digital gift card (use anywhere w/ no fees)? I heard stablecoins were recently dropped to attendees at a conference in Bermuda for use at local gift shops.
We are at all-time highs across the board. It's okay to have a few down days pending Powell on Friday.
News on Viking:
Viking Therapeutics Shares Sink After Obesity Pill Data; Truist Says Sell-Off Overdone
MT Newswires
1:09 PM ET Aug-19-2025
01:09 PM EDT, 08/19/2025 (MT Newswires) -- Shares of Viking Therapeutics (VKTX.NaE) tumbled intraday Tuesday after the company released trial data of its investigational obesity pill.
In a mid-stage trial, patients receiving the highest 120-milligram dose of the VK2735 oral treatment demonstrated a reduction of up to 12.2% in body weight after 13 weeks, the company said in a statement. Analysts were expecting Viking's pill to help reduce weight by 10% to 15%, Reuters reported Tuesday.
"Reductions in body weight were progressive at all doses through the course of the study, with no plateau observed for weight loss at 13 weeks," Viking Therapeutics (VKTX.NaE) said.
While the study showed that the pill was "safe and well-tolerated," about 20% of participants receiving VK2735 discontinued the treatment due to an adverse event, compared with 13% among placebo subjects, according to the statement.
"The most common reasons for treatment discontinuation were gastrointestinal-related adverse events," the company said. The overall discontinuation rate was 28% among VK2735 subjects.
Shares of Vikings slumped 42% in Tuesday trade.
Vikings' stock sell-off is "overdone," Truist Securities said in a report.
"We think the sell-off today is an over-reaction on early results intended to guide late stage clinical development," Truist Managing Director Joon Lee wrote in the note. "We're buyers of the weakness today."
Both Eli Lilly (LLY.NaE) and Novo Nordisk (NVO.NaE) , which currently dominate the weight-loss market, are working to develop obesity pills. Lilly makes the Zepbound weight-loss drug, while Novo offers the Wegovy brand.
Earlier this month, Lilly said its investigational weight-loss pill, orforglipron, showed a 12.4% weight loss in a late stage trial that seemed to disappoint investors. Separately, Novo's oral semaglutide in June showed a weight-loss of 15% over 68 weeks, Reuters reported at the time.
I’m buying the dip. It’s crashing because they’re not ready to launch until October and they haven’t announced the WAC price yet so forecasts can’t be set.
Tonmya should be the next fibromyalgia blockbuster. It Reminds me of Celgene back when it was smaller. GLTAL
ALT is a much better buy.
the side effects for oral GLP-1s are much worse than the injectables and AltImmune got a fast track designation in Alcohol Use disorder today (it also treats MASH and weight loss moving to phase 3 soon).
The RH piece is an interesting one. Since you’re betting against others via buying contracts rather than betting against the house (draftings model), it’s not regulated as gambling. Not sure who came up with it or how it works tbh.
Not sure there is a functional difference between the last two. Who accepts them I guess
I'll be patient and hold for a while. The product seems solid.
@rurahrah000 - at what level would PLTR be a buy?